Dianthus Therapeutics advances Phase 3 CIDP trial early

March 9, 2026 7:09 AM

Dianthus Therapeutics Inc. (NASDAQ: DNTH) announced it reached an early GO decision for its Phase 3 CAPTIVATE trial of claseprubart ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found